Wall Street brokerages forecast that Nevro Corp. (NYSE:NVRO) will report ($0.17) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Nevro’s earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.37). Nevro posted earnings per share of ($0.34) in the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The firm is expected to issue its next earnings report on Thursday, February 22nd.

On average, analysts expect that Nevro will report full-year earnings of ($1.27) per share for the current year, with EPS estimates ranging from ($1.47) to ($1.12). For the next financial year, analysts forecast that the firm will post earnings of ($0.41) per share, with EPS estimates ranging from ($1.35) to $0.32. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Nevro.

Nevro (NYSE:NVRO) last posted its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. The company had revenue of $82.26 million during the quarter, compared to analyst estimates of $80.50 million. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. Nevro’s quarterly revenue was up 35.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.14) earnings per share.

NVRO has been the subject of a number of recent research reports. Canaccord Genuity reduced their target price on shares of Nevro from $120.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, November 7th. Northland Securities reiterated a “buy” rating and issued a $96.00 target price on shares of Nevro in a research report on Tuesday, November 7th. BMO Capital Markets reiterated a “buy” rating and issued a $106.00 target price on shares of Nevro in a research report on Friday, September 1st. TheStreet upgraded Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. Finally, BidaskClub upgraded Nevro from a “sell” rating to a “hold” rating in a research report on Saturday, October 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $100.00.

Shares of Nevro (NVRO) opened at $68.01 on Friday. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59. Nevro has a one year low of $65.40 and a one year high of $99.63.

In related news, Director Michael F. Demane sold 5,000 shares of Nevro stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $93.50, for a total value of $467,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael F. Demane sold 25,000 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $87.73, for a total value of $2,193,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 63,467 shares of company stock worth $5,576,679 in the last three months. Corporate insiders own 12.10% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in Nevro by 36.6% in the second quarter. Bank of Montreal Can now owns 13,187 shares of the medical equipment provider’s stock valued at $982,000 after purchasing an additional 3,534 shares during the last quarter. US Bancorp DE boosted its position in shares of Nevro by 412.4% in the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 2,099 shares during the period. Pictet Asset Management Ltd. boosted its position in shares of Nevro by 68.5% in the second quarter. Pictet Asset Management Ltd. now owns 143,254 shares of the medical equipment provider’s stock worth $9,860,000 after buying an additional 58,227 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Nevro by 12.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 106,598 shares of the medical equipment provider’s stock worth $7,935,000 after buying an additional 11,893 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of Nevro in the second quarter worth about $1,631,000.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Nevro Corp. (NVRO) Will Post Earnings of -$0.17 Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/08/zacks-brokerages-expect-nevro-corp-nvro-will-post-earnings-of-0-17-per-share.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.